TrialFrontiers in immunology2026

Anlotinib combined with chemoradiotherapy for postoperative isolated lymph node recurrence of ESCC: a phase II study.

Jing Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.